Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2012

View Archived Issues

FANG cancer vaccine evaluated in phase I trial

JVRS-100 improves H5N1 vaccine immunogenicity

Novel muscarinic acetylcholine M1 receptor modulators disclosed

U.S. researchers prepare new vaccines

Novel protein kinase inhibitors disclosed by SBI Biotech and CrystalGenomics

NeuroSearch patents novel monoamine neurotransmitter reuptake inhibitors

Roche presents novel AMPK activators

University of Illinois forms new start-up company for cancer products

Medicure to commence SAVI-PCI trial of Aggrastat

Immune Pharmaceuticals granted funds by Israel's Office of the Chief Scientist

Study identifies potential biomarkers of Huntington's disease progression

Transcend-trastuzumab conjugate BT-2111 program advances

AMAG Pharmaceuticals completes enrollment in Feraheme trial

New antibodies designed by Novo Nordisk for hemophilia

Allos Therapeutics requests reexamination of CHMP opinion on Folotyn

FDA approves first treatment for advanced BCC

Health Canada accepts CIP-Isotretinoin submission for review

Jentadueto approved in U.S.

Servier and Monash University establish GPCR collaboration

Domain Therapeutics receives award to develop therapeutics for Parkinson's disease

Orexo ends collaboration with Janssen

Takeda returns Posidur rights to Durect

ATS-907 enters clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...